SrasV1, PubMed, Curation, bibRecord, 002850

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Identifieur interne : 002850 ( PubMed/Curation ); précédent : 002849; suivant : 002851

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Auteurs : Nigel J. Temperton [Royaume-Uni] ; Paul K. Chan ; Graham Simmons ; Maria C. Zambon ; Richard S. Tedder ; Yasuhiro Takeuchi ; Robin A. Weiss

Source :

Emerging infectious diseases [ 1080-6040 ] ; 2005.

RBID : pubmed:15757556

Descripteurs français

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral (blood), Cell Line, Child, Female, Humans, Leukemia Virus, Murine (genetics), Longitudinal Studies, Male, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Middle Aged, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology).
MESH :
- chemical , blood : Antibodies, Viral.
- genetics : Leukemia Virus, Murine, Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Membrane Glycoproteins, SARS Virus, Severe Acute Respiratory Syndrome, Viral Envelope Proteins.
- virology : Severe Acute Respiratory Syndrome.
- Adolescent, Adult, Aged, Aged, 80 and over, Cell Line, Child, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neutralization Tests, Spike Glycoprotein, Coronavirus.

Abstract

The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.

DOI: 10.3201/eid1103.040906
PubMed: 15757556

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002850

Links to Exploration step

pubmed:15757556

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.</title>
<author><name sortKey="Temperton, Nigel J" sort="Temperton, Nigel J" uniqKey="Temperton N" first="Nigel J" last="Temperton">Nigel J. Temperton</name>
<affiliation wicri:level="1"><nlm:affiliation>Wohl Virion Centre and Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, London, UK. nigel.temperton@ucl.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wohl Virion Centre and Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chan, Paul K" sort="Chan, Paul K" uniqKey="Chan P" first="Paul K" last="Chan">Paul K. Chan</name>
</author>
<author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name>
</author>
<author><name sortKey="Zambon, Maria C" sort="Zambon, Maria C" uniqKey="Zambon M" first="Maria C" last="Zambon">Maria C. Zambon</name>
</author>
<author><name sortKey="Tedder, Richard S" sort="Tedder, Richard S" uniqKey="Tedder R" first="Richard S" last="Tedder">Richard S. Tedder</name>
</author>
<author><name sortKey="Takeuchi, Yasuhiro" sort="Takeuchi, Yasuhiro" uniqKey="Takeuchi Y" first="Yasuhiro" last="Takeuchi">Yasuhiro Takeuchi</name>
</author>
<author><name sortKey="Weiss, Robin A" sort="Weiss, Robin A" uniqKey="Weiss R" first="Robin A" last="Weiss">Robin A. Weiss</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15757556</idno>
<idno type="pmid">15757556</idno>
<idno type="doi">10.3201/eid1103.040906</idno>
<idno type="wicri:Area/PubMed/Corpus">002850</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002850</idno>
<idno type="wicri:Area/PubMed/Curation">002850</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002850</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.</title>
<author><name sortKey="Temperton, Nigel J" sort="Temperton, Nigel J" uniqKey="Temperton N" first="Nigel J" last="Temperton">Nigel J. Temperton</name>
<affiliation wicri:level="1"><nlm:affiliation>Wohl Virion Centre and Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, London, UK. nigel.temperton@ucl.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wohl Virion Centre and Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chan, Paul K" sort="Chan, Paul K" uniqKey="Chan P" first="Paul K" last="Chan">Paul K. Chan</name>
</author>
<author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name>
</author>
<author><name sortKey="Zambon, Maria C" sort="Zambon, Maria C" uniqKey="Zambon M" first="Maria C" last="Zambon">Maria C. Zambon</name>
</author>
<author><name sortKey="Tedder, Richard S" sort="Tedder, Richard S" uniqKey="Tedder R" first="Richard S" last="Tedder">Richard S. Tedder</name>
</author>
<author><name sortKey="Takeuchi, Yasuhiro" sort="Takeuchi, Yasuhiro" uniqKey="Takeuchi Y" first="Yasuhiro" last="Takeuchi">Yasuhiro Takeuchi</name>
</author>
<author><name sortKey="Weiss, Robin A" sort="Weiss, Robin A" uniqKey="Weiss R" first="Robin A" last="Weiss">Robin A. Weiss</name>
</author>
</analytic>
<series><title level="j">Emerging infectious diseases</title>
<idno type="ISSN">1080-6040</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Viral (blood)</term>
<term>Cell Line</term>
<term>Child</term>
<term>Female</term>
<term>Humans</term>
<term>Leukemia Virus, Murine (genetics)</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Middle Aged</term>
<term>Neutralization Tests</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Anticorps antiviraux (sang)</term>
<term>Enfant</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Mâle</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Tests de neutralisation</term>
<term>Virus de la leucémie murine (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Études longitudinales</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Leukemia Virus, Murine</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Virus de la leucémie murine</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cell Line</term>
<term>Child</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neutralization Tests</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tests de neutralisation</term>
<term>Études longitudinales</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15757556</PMID>
<DateCompleted><Year>2005</Year>
<Month>04</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-6040</ISSN>
<JournalIssue CitedMedium="Print"><Volume>11</Volume>
<Issue>3</Issue>
<PubDate><Year>2005</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Emerging infectious diseases</Title>
<ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.</ArticleTitle>
<Pagination><MedlinePgn>411-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Temperton</LastName>
<ForeName>Nigel J</ForeName>
<Initials>NJ</Initials>
<AffiliationInfo><Affiliation>Wohl Virion Centre and Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, London, UK. nigel.temperton@ucl.ac.uk</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Paul K</ForeName>
<Initials>PK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Simmons</LastName>
<ForeName>Graham</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zambon</LastName>
<ForeName>Maria C</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tedder</LastName>
<ForeName>Richard S</ForeName>
<Initials>RS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Takeuchi</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Weiss</LastName>
<ForeName>Robin A</ForeName>
<Initials>RA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Infect Dis</MedlineTA>
<NlmUniqueID>9508155</NlmUniqueID>
<ISSNLinking>1080-6040</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009052" MajorTopicYN="N">Leukemia Virus, Murine</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>3</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>3</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15757556</ArticleId>
<ArticleId IdType="pmc">PMC3298259</ArticleId>
<ArticleId IdType="doi">10.3201/eid1103.040906</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol Methods. 2004 Sep 1;120(1):87-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15234813</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2004 Aug 15;326(1):140-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15262502</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Sep;78(17):9007-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15308697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2004 Sep 15;190(6):1119-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15319862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1996 Apr 12;272(5259):263-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8602510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Microbiol. 2004 May;53(Pt 5):435-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12295-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11027299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1715-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11788023</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leukemia. 2002 Feb;16(2):254-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11840292</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11920-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12154231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Biotechnol. 2002 Oct;13(5):437-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12459334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):508-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12890855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14199-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14617769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2468-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Mar 5;315(2):439-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14766227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15242938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2004 Feb;4(2):64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14959754</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Diagn Lab Immunol. 2004 Mar;11(2):362-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15013989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):304-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1158-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15031782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Mar;10(3):530-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15109430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 May;42(5):2306-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15131220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 9;319(4):1216-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jul;78(13):6938-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jul;78(13):7217-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194798</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 May;10(5):825-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15200815</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002850 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002850 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15757556
   |texte=   Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:15757556" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki